ENGLEWOOD, Colo., March 19, 2021 /PRNewswire/ -- Ampio
Pharmaceuticals (NYSE American: AMPE), a clinical stage
biopharmaceutical company focused on the advancement of
immunology-based therapies for prevalent inflammatory conditions,
today announced that it has been invited to present at the Benzinga
Biotech Small Cap Conference being held virtually on March 24 & 25, 2021.
Details are as follows:
Corporate Overview
Title: Ampio – Business & Pipeline Update
Date: March 24, 2021
Time: 2:00-2:20pm EDT on
Track 2
Registration
Link: https://www.benzinga.com/events/small-cap/biotech/
About Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc. is a clinical stage
biopharmaceutical company primarily engaged in the development of
AmpionTM, our lead anti-inflammatory drug, which is
currently undergoing clinical trials focused on the treatment of
patients afflicted with COVID-19 induced acute respiratory distress
syndrome (ARDS) as well as patients suffering from severe (KL-4)
osteoarthritis of the knee (OAK). Both conditions impact a
significant percentage of the population and due to the lack of any
FDA approved drugs for treatment, there exists a significant unmet
medical need. Ampion is backed by an extensive global patent
portfolio with intellectual property protection extending through
2035. In addition, Ampion will be eligible for 12-year FDA
market exclusivity upon approval as a novel biologic under the
biologics price competition and innovation act (BPCIA).
Forward Looking Statements
Ampio's statements in this press release that are not historical
fact, and that relate to future plans or events, are
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by the use of words such as "believe,"
"expect," "plan," "anticipate," and similar expressions. These
forward-looking statements include statements regarding Ampio's
expectations with respect to Ampion and its classification, as
well as those associated with regulatory approvals and other FDA
decisions, the Biological License Application ("BLA"), the ability
of Ampio to enter into partnering arrangements,
clinical trials and decisions and changes in business
conditions and similar events, the ability to receive regulatory
approval to conduct clinical trials, that Ampion may be used to
treat ARDS induced by COVID-19, all of which are inherently subject
to various risks and uncertainties. The risks and uncertainties
involved include those detailed from time to time in Ampio's
filings with the Securities and Exchange Commission, including
without limitation, under Ampio's Annual Report on Form 10-K and
other documents filed with the Securities and Exchange Commission.
Ampio undertakes no obligation to revise or update these
forward-looking statements, whether as a result of new information,
future events or otherwise.
Company Contacts
Investor Relations
Joe
Hassett
joeh@gregoryfca.com
484-686-6600
Media Contact
Katie
Kennedy
katie@gregoryfca.com
610-731-1045
View original content to download
multimedia:http://www.prnewswire.com/news-releases/ampio-pharmaceuticals-to-present-at-benzinga-biotech-small-cap-conference-301250887.html
SOURCE Ampio Pharmaceuticals, Inc.